Evotec SE EVO
NASDAQ EVO
$1.75 -0.06 (-3.34%)
As of: Sep 10, 2026 · 9:41 AM EDT

Evotec SE (EVO) Depreciation & Amortization (CF) (2009 - 2019)

Evotec SE's (EVO) quarterly Depreciation & Amortization (CF) came in at $40.0 million in Q4 2019, up 147564.08% quarter-over-quarter from $27116.7 in Q3 2010.

Analysis

Evotec SE (EVO) Depreciation & Amortization (CF) (2009 - 2019) Analysis & Trends

Evotec SE has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $40.0 million for Q4 2019.

  • In Q4 2019, Depreciation & Amortization (CF) changed N/A year-over-year to $40.0 million; the TTM figure through Mar 2021 stood at $40.0 million (changed N/A YoY), while the FY2025 annual figure was $112.4 million, up 2.19% from the prior year.
  • Depreciation & Amortization (CF) came in at $40.0 million for Q4 2019 at Evotec SE, up from $27116.7 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $40.0 million in Q4 2019 to a low of $40.0 million in Q4 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Iqvia Holdings 42.19 Bn 40.11 Bn 1.44 Bn 292.00 Mn
2 Medpace Holdings 16.41 Bn 15.91 Bn 201.64 Mn -
3 Charles River Laboratories International 13.16 Bn 12.97 Bn 452.07 Mn 67.29 Mn
4 Icon 12.37 Bn 11.44 Bn 479.29 Mn 90.77 Mn
5 Fortrea Holdings 1.55 Bn 1.39 Bn 139.20 Mn 19.60 Mn
6 Evotec SE 621.52 Mn 195.65 Mn - -
7 Ginkgo Bioworks Holdings 419.14 Mn 334.60 Mn 18.44 Mn 12.32 Mn
8 Champions Oncology 71.79 Mn 71.79 Mn 7.03 Mn 321,000.00
9 MindWalk Holdings 59.83 Mn 51.55 Mn 1.82 Mn 173,622.43
10 VivoSim Labs 1.45 Mn 1.45 Mn - 40,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 40.04 Mn
Sep 30, 2010 27,116.73
Jun 30, 2010 167,003.71
Mar 31, 2010 178,627.56
Dec 31, 2009 237,754.21
Jun 30, 2009 140,249.78
Mar 31, 2009 102,003.22